Description
OVERVIEWProduct overview
CJC-1295 with DAC is an analogue of the first 29 residues of growth hormone releasing hormone, carrying a maleimide drug affinity complex that binds serum albumin after administration.
Albumin binding markedly extends the profile of the peptide in animal studies compared with the unmodified sequence, which is the reason it is chosen for longer-duration protocols.
Supplied as a research compound only.
SUPPLY IN IRELANDCJC-1295 with DAC Ireland — supplied to research laboratories
Research groups across Ireland buy CJC-1295 with DAC from Kensington Laboratories as a lyophilised CJC-1295 with DAC peptide, released only against a batch-matched certificate of analysis. Every vial of high purity CJC-1295 with DAC is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering CJC-1295 with DAC in Ireland receive material with documented purity and identity.
Laboratory CJC-1295 with DAC is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning CJC1295withDAC research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for CJC-1295 with DAC peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
CJC-1295 with DAC is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 5 mg per vial
- Peptide class: Growth hormone releasing hormone analogue with a drug affinity complex
- Also known as: Modified GRF (1-29) with drug affinity complex
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
CJC-1295 with DAC is an analogue of the first 29 residues of growth hormone releasing hormone, carrying a maleimide drug affinity complex that binds serum albumin after administration.
Albumin binding markedly extends the profile of the peptide in animal studies compared with the unmodified sequence, which is the reason it is chosen for longer-duration protocols.
Supplied as a research compound only.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- GHRH receptor pathway studies
- Extended-profile versus short-profile comparisons
- Pulsatile versus sustained signalling models
- Albumin binding and peptide half-life research
Scientific context and proposed mechanisms
The peptide binds the GHRH receptor on pituitary somatotrophs; the affinity complex conjugates to circulating albumin, slowing clearance in study models.
Its long profile makes it a common comparison arm against the without-DAC sequence in pulsatility experiments.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-CJC1295WIT-2408A
- Testing laboratory
- Colmaric Analyticals
- Date tested
- 21 July 2026
- Reported purity
- 99.57%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
The independent result for this batch is summarised above. Contact the laboratory team if you need the full report for this batch.
